Scilex Holding Company (SCLX) all U.S. Lobbying: all historical lobbying contracts, government bills & agencies, and critical issues lobbied on.

$99.95

Discover Scilex Holding Company’s lobbying activities with our comprehensive dataset, offering insights on spending, bills, and issues from 1999-present. Analyze data by company, lobbyist, issue, and more through our intelligently crafted data design. Dataset updated weekly.

Description

Using our intelligently designed and intuitive dataset, you can quickly understand how Scilex Holding Company (SCLX) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.

Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.

For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.

Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.

Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:

1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.

2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.

3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).

4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.

5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).

6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).

7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).

Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].

Frequently Asked Questions

What is Scilex Holding Company (SCLX) lobbying for?

Summary:

– Lobbying firms: Tauzin Strategic Networks, Tauzin Consultants, Llc
– General issues: Medicare/Medicaid, Health Issues
– Specific issues: prior authorization, COVID-19, fair competition, non-opioid alternatives, the Lower Health Care Costs Act, Patient Affordability Value and Efficiency Act, generic drug market, drug costs, pain management, S.1895
– Government agencies: Senate, Food & Drug Administration (FDA), House of Representatives

One could infer that Scilex Holding Company is lobbying on issues related to healthcare and COVID-19 in order to influence legislation that may impact their business in those areas. Specifically, their focus on non-opioid alternatives and pain management suggests that they may be a pharmaceutical company seeking to promote their own non-opioid products. Their lobbying on issues related to fair competition and drug costs may also indicate that they are trying to protect their market share or influence pricing policies.

Subscribe To Our Newsletter

gain actionable insights from our alternative data

More to explore